CC-220 enhances the degradation of IKZF1 and IKZF3,261 showing significant anti-proliferative activity in various diseases, particularly in systemic lupus erythematosus and R/R MM.262–264 Preclinical studies indicate that CC-220 is more effective than bortezomib and pomalidomide, especially in combination with daratumumab, where it shows synergistic effects against resistant MM cells.265 In clinical trials, CC-220 has demonstrated promising efficacy and safety profiles. Here, IKZF1 is linked to Miyoshi myopathy.